Gossamer Bio Inc stock (US38198T1034): shares in focus after securities lawsuit update and elevated short interest

Gossamer Bio shares on Nasdaq remain under pressure as a fresh securities fraud lawsuit reminder and high short interest keep the United States biotech name in the spotlight, while the stock trades near the lower end of its recent range.

Gossamer Bio Inc, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker GOSS in the United States, stayed in the spotlight this week as its depressed share price, elevated short interest and a new reminder of a pending securities fraud lawsuit continued to shape investor sentiment. According to MarketBeat, the stock last closed at USD 0.22 on Nasdaq on 05/27/2026, effectively flat in after-hours trading and near multi-year lows for the San Diego-based biotech name, underscoring continued risk appetite challenges in the small-cap US biotech space. While no new earnings release has been filed in the past few days, trading activity and legal headlines mean the stock remains closely watched by traders who focus on high-volatility, high-short-interest names in the US market.

The legal angle was brought back into focus on 05/27/2026, when a PR Newswire notice reported that Gossamer Bio shareholders who lost money have an opportunity to lead a securities fraud lawsuit, highlighting alleged misstatements and losses tied to earlier disclosures. The reminder of litigation risk arrives at a time when the company is already dealing with a constrained valuation, which can influence how market participants in the United States price regulatory and legal overhang. Gossamer Bio has previously communicated through its investor relations site that it remains focused on its research programs, but legal actions can still add uncertainty around potential future costs and management attention. In Germany, the stock is also available to retail investors on venues such as Tradegate, where it typically trades at a low single-digit euro-cent price level, extending its reach into the broader European retail trading community.

From a trading-structure perspective, short interest data underline that Gossamer Bio remains a heavily shorted US biotech stock. MarketBeat data show that as of 05/15/2026, short interest stood at approximately 40.84 million shares, equal to around 18.75% of the public float, with a reported days-to-cover ratio of 11.5 based on an average daily trading volume of 13.25 million shares. This means that if short sellers sought to close their positions, it would take multiple trading days at typical volume levels, a configuration that can amplify volatility around news or corporate events. The stock therefore trades in a segment of the US market where sentiment swings, liquidity conditions, and regulatory headlines quickly feed into price dynamics. For retail investors following US biotech names via German platforms, these short-interest figures are often a key data point in assessing risk but also potential for sharp counter-moves when sentiment shifts.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Gossamer Bio Inc
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: San Diego, United States
• Core markets: United States and other major pharmaceutical markets
• Key revenue drivers: Future milestone and potential product revenues from late-stage and earlier-stage drug candidates
• Home exchange/listing venue: Nasdaq (GOSS)
• Trading currency: USD

Gossamer Bio Inc: core business model

Gossamer Bio Inc concentrates on discovering and developing clinical-stage therapeutics in disease areas such as immunology and inflammation, with the aim of eventually generating revenue from successful drug approvals and strategic collaborations or licensing agreements.

Industry trends and competitive position

The broader US biotech and biopharmaceutical sector has seen a challenging funding backdrop over the past two years, with many smaller clinical-stage companies facing pressure on valuations as investors reassess risk exposure, and Gossamer Bio is operating in this environment as one of many early- and mid-stage pipeline-focused names. Larger peers and competitors include companies such as Amgen and Bristol Myers Squibb that participate in immunology and inflammation markets with commercial-stage portfolios, while Gossamer Bio remains earlier in the lifecycle and more dependent on clinical trial milestones for value creation. According to sector analysts at providers like S&P Global, the industry continues to see robust long-term demand for innovative therapies in chronic diseases, but capital allocation has become more selective, favoring companies with differentiated data, strong balance sheets, or clear partnering paths. This means that smaller issuers such as Gossamer Bio must compete not only on science but also on their ability to secure funding and partnerships in a more cautious market.

Conclusion

Gossamer Bio Inc remains in focus on Nasdaq as a United States biotech stock with a low absolute share price, significant short interest and a newly highlighted securities fraud lawsuit opportunity that reinforces legal overhang for shareholders. The company continues to operate in a competitive biopharmaceutical landscape that favors strong clinical data and robust funding access, factors that can be particularly important for small-cap issuers seeking to progress their pipelines. How the combination of litigation risk, sector conditions and future clinical or financing updates evolves will likely determine whether the stock can move away from its current low trading range or continues to trade mainly as a high-risk, sentiment-driven biotech name.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.